Cancer medicine is sometimes ineffective. A study that reveals the causes

In a new step toward cancer treatment, a recent extensive study showed accurate details on genetic mutations responsible for resistance to medicine in cancer cells. The study conducted prestigious scientific institutions, such as the Wilcum Singer Institute and the European Biomedical Information Institute (EMBL-IBI), in conjunction with open targets. The research focused on colon and lung cancer, as new categories of medicine -resistant mutations have been identified, which can open the way for innovative treatments, and to determine therapeutic options for patients based on the genetic structure of their crops. Cancer medicine resistance and medicine resistance are one of the biggest challenges facing cancer treatment, and over time cancer cells are less in response to traditional treatments, which require the search for other treatment options known as the second line treatments. The research team understood how the resistance occurred more precisely, and used genetics techniques (CISPR) to study the effect of mutations on the effectiveness of 10 cancer medicines, with the aim of identifying effective treatments based on the genetic composition of patients. The research was based on crispr techniques for genetics, and accurate genomic technologies to study the response of cancer cells to treatments. The map of genetic mutations and through these techniques researchers were able to create an extensive map of drug -resistant genetic mutations. The researchers believe that this map is not only an instrument to understand the mechanisms of medicine resistance, but also a way to determine new mutations, which can be important indication of treatment, and offers complex therapeutic options or from the second line. The researchers, in the study published in the journal Nature Genetics, explain that the mutations that cause medicine resistance are divided into four main categories: the first of which is the medicine -resistant mutations, which are genetic changes that make the drug less effective in eliminating cancer, by preventing the connection with the goal within the cancer. The second boom is those that depend on medicine, as some cancer cells depend on the cure for their growth instead of eliminating it, which supports the idea of ​​temporarily stopping the treatment to eliminate these cells. The third category is the stimulating mutation, which gives cancer cells the ability to use alternative signals for growth, bypassing the targeted paths, while the allergic mutations of the medicine are changes that make cells more sensitive to certain treatments, which means patients who wear these mutations can benefit from specific medicines. Personal medicine for cancer treatment. The researchers say the study is an important step in developing personal medicine for cancer. By understanding the types of resistance mutations, doctors can make more accurate decisions about treatment, such as temporarily stopping treatment in the case of medicine -based mutations, or using certain medications when allergic mutations are present. This deep understanding can accelerate the development of new medicines to prevent the rise of treatment. The first author of the study, dr. Matthew Coelho, a researcher at the Wilcum singer Institute, says that developing cancer cells and their resistance to treatment is a major problem, which provides a quick way to identify these mutations in patients and understanding how to combat it is essential for cancer treatment. New treatments for cancer and add: “By classifying mutations into four different categories, we can define different treatment methods, such as taking advantage of the medicine -based mutations by temporarily stopping the treatment.” The researchers also say that the combination of genetic liberalization techniques and machine learning enabled the team to draw a detailed map of medicine -resistance mechanisms at the level of individual mutations; Not only is the map a tool to understand the current mutations, but it can be a guide to develop new clinical experiences aimed at these mutations. This study is the beginning of a new approach to the development of cancer treatments; Pharmaceutical businesses can begin to develop inhibitors aimed at these mutations before resistance appears in clinics, creating a preventative approach that can help avoid the major problem of medicine resistance, which provides more effective treatment options for patients.